What's Happening?
Trellis Bioscience, a biotechnology company based in Redwood City, California, has successfully closed a $9 million Series C financing round. This funding will support the completion of the company's Phase 2 trial of calpurbatug (TRL1068), an investigational
monoclonal antibody treatment for chronic prosthetic joint infections (PJI). The Series C round saw participation from existing investors such as New Science Ventures and Easton Capital, as well as new investors including the AMR Action Fund and The Doctor Group of Dallas, Texas. The total equity funding for Trellis now stands at approximately $35 million, complemented by non-dilutive grant support from the National Institute of Allergy and Infectious Disease and CARB-X. The company aims to address the challenging and costly issue of PJIs, which affect a significant number of joint replacement recipients annually in the U.S.
Why It's Important?
The development of calpurbatug (TRL1068) is significant as it represents a potential breakthrough in treating antibiotic-resistant infections associated with prosthetic joint replacements. PJIs are a major healthcare challenge, with current treatments involving invasive surgical procedures that have high failure rates and substantial costs. Trellis's approach, which targets the biofilm that protects bacteria from antibiotics, could offer a less invasive and more effective treatment option. This advancement is crucial as the aging U.S. population is expected to undergo more joint replacement surgeries, increasing the demand for effective PJI treatments. The support from prominent investors highlights the potential impact of Trellis's work in the field of infectious diseases.
What's Next?
Trellis Bioscience is currently conducting a Phase 2 trial of TRL1068 in PJI patients, with top-line results expected in the second quarter of 2027. The company has received Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations from the FDA, which may expedite the development and regulatory review process. If successful, TRL1068 could become a new standard of care for managing PJIs, potentially reducing the need for invasive surgeries and improving patient outcomes. The continued support from investors and the promising early clinical results suggest a positive outlook for the future of this treatment.
